Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

bispecific monoclonal antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CD19 (1) CD3 (1) CTLA-4 (1) EGFR (3) Factor VIII (1) IGF-1R (1) Interleukin Related (2) LAG-3 (1) PD-1/PD-L1 (1) Tie (1) TNF Receptor (2) VEGFR (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (1) Inflammation/Immunology (4)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9963

Blinatumomab 1 Publications Verification Anatumomab	CD19	Cancer
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .

HY-P99663

Inezetamab	TNF Receptor	Cancer
Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody .

HY-P99380

Zanidatamab ZW 25	EGFR	Cancer
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .

HY-P9940

Emicizumab	Factor VIII	Cardiovascular Disease
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .

HY-P99676

Izalontamab SI-B001	EGFR	Cancer
Izalontamab (SI-B001) is a bispecific *anti-EGFR/HER3* monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .

HY-P99330

Vanucizumab Anti-Human VEGFA Recombinant antibody; RO5520985	VEGFR Tie	Cancer
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .

HY-P99166

Vudalimab	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

HY-P99563

Tibulizumab LY 3090106	TNF Receptor Interleukin Related	Inflammation/Immunology
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research .

HY-P99354

Bavunalimab Anti-Human CTLA4xLAG3	LAG-3	Inflammation/Immunology Cancer
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .

HY-P99672

Istiratumab MM 141; MM-005	IGF-1R EGFR	Cancer
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .

HY-P99385

Vobarilizumab ALX-0061	Interleukin Related	Inflammation/Immunology
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (K_d: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .

HY-P99390

Tepoditamab MCLA 117	CD3	Cancer
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .

Cat. No.	Product Name	Target	Research Area

HY-P9963

Blinatumomab 1 Publications Verification Anatumomab	CD19	Cancer
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .

HY-P99663

Inezetamab	TNF Receptor	Cancer
Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody .

HY-P99380

Zanidatamab ZW 25	EGFR	Cancer
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .

HY-P9940

Emicizumab	Factor VIII	Cardiovascular Disease
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .

HY-P99676

Izalontamab SI-B001	EGFR	Cancer
Izalontamab (SI-B001) is a bispecific *anti-EGFR/HER3* monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .

HY-P99330

Vanucizumab Anti-Human VEGFA Recombinant antibody; RO5520985	VEGFR Tie	Cancer
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .

HY-P99166

Vudalimab	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

HY-P99563

Tibulizumab LY 3090106	TNF Receptor Interleukin Related	Inflammation/Immunology
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research .

HY-P99354

Bavunalimab Anti-Human CTLA4xLAG3	LAG-3	Inflammation/Immunology Cancer
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .

HY-P99672

Istiratumab MM 141; MM-005	IGF-1R EGFR	Cancer
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .

HY-P99385

Vobarilizumab ALX-0061	Interleukin Related	Inflammation/Immunology
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (K_d: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .

HY-P99390

Tepoditamab MCLA 117	CD3	Cancer
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .

Blinatumomab 1 Publications Verification Anatumomab	Classification of Application Fields Disease Research Fields Cancer	CD19
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .

Zanidatamab ZW 25	Classification of Application Fields Disease Research Fields Cancer	EGFR
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .

Izalontamab SI-B001	Classification of Application Fields Disease Research Fields Cancer	EGFR
Izalontamab (SI-B001) is a bispecific *anti-EGFR/HER3* monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .

Vanucizumab Anti-Human VEGFA Recombinant antibody; RO5520985	Classification of Application Fields Disease Research Fields Cancer	VEGFR Tie
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .

Vudalimab	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1 CTLA-4
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

Istiratumab MM 141; MM-005	Classification of Application Fields Disease Research Fields Cancer	IGF-1R EGFR
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

bispecific monoclonal antibody

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Natural
Products